m6A demethylase ALKBH5 attenuates doxorubicin-induced cardiotoxicity via posttranscriptional stabilization of Rasal3

Ri-Feng Gao,Kun Yang,Ya-Nan Qu,Xiang Wei,Jia-Ran Shi,Chun-Yu Lv,Yong-Chao Zhao,Xiao-Lei Sun,Ying-Jia Xu,Yi-Qing Yang

DOI: https://doi.org/10.1016/j.isci.2023.106215

IF: 5.8

2023-03-01

iScience

Abstract:The clinical application of anthracyclines such as doxorubicin (DOX) is limited due to their cardiotoxicity. N6-methyladenosine (m⁶A) plays an essential role in numerous biological processes. However, the roles of m⁶A and m⁶A demethylase ALKBH5 in DOX-induced cardiotoxicity (DIC) remain unclear. In this research, DIC models were constructed using <i>Alkbh5</i>-knockout (KO), <i>Alkbh5</i>-knockin (KI), and <i>Alkbh5</i>-myocardial-specific knockout (ALKBH5^{flox/flox, αMyHC-Cre}) mice. Cardiac function and DOX-mediated signal transduction were investigated. As a result, both <i>Alkbh5</i> whole-body KO and myocardial-specific KO mice had increased mortality, decreased cardiac function, and aggravated DIC injury with severe myocardial mitochondrial damage. Conversely, ALKBH5 overexpression alleviated DOX-mediated mitochondrial injury, increased survival, and improved myocardial function. Mechanistically, ALKBH5 regulated the expression of Rasal3 in an m⁶A-dependent manner through posttranscriptional mRNA regulation and reduced <i>Rasal3</i> mRNA stability, thus activating RAS3, inhibiting apoptosis through the RAS/RAF/ERK signaling pathway, and alleviating DIC injury. These findings indicate the potential therapeutic effect of ALKBH5 on DIC.

multidisciplinary sciences